newsfilter
← Latest News
GlobeNewswire·

Kaplan Fox & Kilsheimer LLP is Investigating Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) for Potential Securities Law Violations

  • Kaplan Fox & Kilsheimer LLP is investigating potential securities violations by Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL).
  • On November 3, 2026, Madrigal filed a Form 10-Q revealing a whistleblower complaint filed by a former employee on October 9, 2026, in the Northern District of Illinois.
  • The complaint alleges retaliation under the Sarbanes-Oxley Act of 2002 regarding internal concerns about company data & reporting practices raised prior to the employee's resignation in January 2026.
  • Madrigal disputes the allegations & plans to vigorously defend itself against the lawsuit.
  • Following the disclosure, Madrigal stock fell 8.08% from $431.16 on November 2, 2026, to close at $396.32 on November 3, 2026.
  • Kaplan Fox & Kilsheimer LLP invites investors who suffered losses to contact the firm via email or phone for potential participation in the investigation.
Company
Kaplan Fox & Kilsheimer, LLP
Keywords
Kaplan Fox & Kilsheimer, LLP, MDGL Investor Alert, MDGL Investigation, NASDAQ: MDGL, $MDGL, Shareholder Alert, Securities Investigation, Kaplan Fox, Class Action